Overview

MeSH Major

Antibodies, Monoclonal, Humanized

Antineoplastic Agents

Breast Neoplasms

Maytansine

Receptor, ErbB-2

abstract

Tumor response rates were lower than in prior reports of trastuzumab-resistant, HER2-positive MBC, but one third of patients received therapy with T-DM1 for ≥ 6 months, which suggests a clinically relevant benefit in patients who received prior pertuzumab.